A key milestone has just been achieved toward marketing Noveko(TM)
antimicrobial face masks in the European Economic Space countries.
EKO / TSX Venture Exchange
MONTREAL, July 10 /CNW Telbec/ - Noveko International Inc. is pleased to
announce that its subsidiary Noveko Inc., which develops biomedical and
environmental products derived from its patented antimicrobial filtration
technology (Noveko(TM) antimicrobial face masks and air filters), has obtained
CE Marking for its antimicrobial face masks.
This mandatory regulatory marking indicates that the Noveko(TM) face
masks comply with the requirements of the European Directives in regard to
public health, safety and consumer protection, and allow the relevant products
to freely move throughout the European Economic Space countries.
"Obtaining CE Marking for our antimicrobial face masks is excellent news.
This very important certification allows us to access the European Economic
Space markets, including 30 countries and representing a population of close
to a half-billion residents. In addition, CE Marking for medical supplies and
devices is recognized by most African countries, giving us access to another
major potential market of approximately one billion people. We are thus laying
down the bases to adequately meet demand and expect to finalize agreements
with manufacturers and distributors within the coming weeks," indicated Alain
Bolduc, President and Chief Operating Officer of Noveko.
Noveko International Inc. is a public holding company. Currently, its
operating subsidiaries are S.A.S. ECM, Noveko Inc., Laboratoire SyMa Inc.,
Bolduc Leroux Inc. and Magnum Pharmaceutics Inc. ECM specializes in portable
real-time ultrasound scanners for veterinary and human medicine. Noveko Inc.
develops biomedical and environmental products derived from its patented
antimicrobial filtration technology (Noveko(TM) antimicrobial face masks and
air filters). SyMa specializes in sanitizers, sold under the Azuro(TM) brand.
BLI is involved in the custom processing and distribution of steel products
based on client specifications. Magnum acts as a manufacturer sales agent for
the Noveko Group's biomedical and environmental products and sanitizers and
for other manufacturers.
The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange has
not reviewed and does not accept responsibility for the adequacy or accuracy
of this release.
For further information:
For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, Noveko
International Inc., (514) 344-3030; http://www.noveko.com